weekend musing about uk ai opp: – why does the uk still not have a homegrown peer to openai, anthropic, mistral, xai, sakana, poolside or others that build frontier models? – why has it taken almost a decade for any remotely serious gov-backed policy to be endorsed despite the
INVESTMENT
-
Questionable spending plan raises investor accountability concerns
By
–
fwiw that spend plan sounds incredibly sketch, and if they manage to raise that'd be impressively bubbly, and the investor needs to look themselves in the mirror.
-
Are Pretraining Startups Still Viable in 2026?
By
–
are people still starting pretraining companies? I thought that was sooo 2023/2024.
-
OpenAI Plus Feature Availability and API Pricing Updates
By
–
will be available with openai plus; still working on api pricing but not that much.
-
Funding aimed at AI-driven health prediction and advanced sensors
By
–
Les 65 millions ont été répartis en trois phases :
— Jouhatsu | AI Influence Operator (@Jouhatsu_ai) 10 janvier 2025
• Construire les capteurs de santé les plus avancés au monde
⁰• Créer une IA capable de prédire les problèmes de santé
⁰• Nouer des partenariats avec des institutions médicales
Mais le génie résidait dans les détails : pic.twitter.com/qgDHEuOckiLes 65 millions ont été répartis en trois phases : • Construire les capteurs de santé les plus avancés au monde
• Créer une IA capable de prédire les problèmes de santé
• Nouer des partenariats avec des institutions médicales Mais le génie résidait dans les détails : -
Open-Source AI Dominance: Geopolitical Power and Strategic Influence
By
–
Or impact of the fact that closed-source players use open-source AI (currently dominated by Chinese players) like open-source datasets? The countries or companies that win open-source AI will have massive power and influence on the future of AI.
-
US Big Tech dominance skews AI market performance metrics
By
–
NEW STREET TALK ON @AIRSTREETPRESS – 10 JAN 2025 1. Market commentators don’t always agree that AI exists
If you minus out US big tech, then over the last couple of years (since Oct 2022), the S&P has in fact not outperformed its European counterparts. We’ve seen many versions -
Building AI-First Bio Companies: Software Market Challenges
By
–
for an excellent first-hand take into the challenge of building ai-first bio companies, please read @agupta
’s essay “how unfair is the coin” in it he discusses:
– why selling software to pharma isn’t really a market – why software-only in bio ultimately converges to “make -
R&D Staff Equity Compensation Valuation Impact Analysis
By
–
hmmm the “incl equity” part to r&d staff comp probably misrepresents things bc just consider the valuation change of these companies as they grow bigger and better models – it goes up a lot.
-
DeepSeek Engineering Efficiency vs Big Tech Capital Expenditures
By
–
“The paths are clear. DeepSeek shows that a lot of the modern AI pipeline is not magic — it’s consistent gains accumulated on careful engineering and decision making. In face of the dramatic capital expenditures from Big Tech, billion dollar fundraises from Anthropic and